VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, December 29, 2025
Stock Comparison
Bristol-Myers Squibb Company vs DSM-Firmenich AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisDSM-Firmenich AG
DSFIR · Euronext Amsterdam
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into DSM-Firmenich AG's moat claims, evidence, and risks.
View DSFIR analysisComparison highlights
- Moat score gap: DSM-Firmenich AG leads (63 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); DSM-Firmenich AG has 4 segments (31% in Perfumery & Beauty).
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; DSM-Firmenich AG has 10 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
DSM-Firmenich AG
Perfumery & Beauty
B2B fragrances, perfumery ingredients, and beauty ingredients
Global
Consumer brands (fine fragrance, personal care, home care) and beauty brands
Ingredient supplier / fragrance house (co-creation + ingredient palette)
31%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
DSM-Firmenich AG strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
DSM-Firmenich AG segments
Full profile >Perfumery & Beauty
Oligopoly
Taste, Texture & Health
Oligopoly
Health, Nutrition & Care
Competitive
Animal Nutrition & Health
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.